Werewolf banks $72M to shepherd shape-shifting cancer meds into phase 1
Werewolf banks $72M to shepherd shape-shifting cancer meds into phase 1 A year after coming out of the shadows, Werewolf Therapeutics is kicking it up a notch. With $72 million in new financing, the company will push two shape-shifting cytokine drugs into the clinic and ramp up its discovery and preclinical work. Werewolf is working […]
Read More